1. Home
  2. SLNG vs BMEA Comparison

SLNG vs BMEA Comparison

Compare SLNG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stabilis Solutions Inc.

SLNG

Stabilis Solutions Inc.

HOLD

Current Price

$4.51

Market Cap

92.0M

Sector

Utilities

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.34

Market Cap

87.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNG
BMEA
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.0M
87.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SLNG
BMEA
Price
$4.51
$1.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$10.00
$8.71
AVG Volume (30 Days)
6.2K
1.1M
Earning Date
02-24-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$72,270,000.00
N/A
Revenue This Year
$7.02
N/A
Revenue Next Year
$7.68
N/A
P/E Ratio
$80.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.29
$0.87
52 Week High
$8.28
$4.59

Technical Indicators

Market Signals
Indicator
SLNG
BMEA
Relative Strength Index (RSI) 47.85 54.18
Support Level $4.33 $1.23
Resistance Level $4.65 $1.37
Average True Range (ATR) 0.29 0.08
MACD -0.01 0.00
Stochastic Oscillator 49.45 74.73

Price Performance

Historical Comparison
SLNG
BMEA

About SLNG Stabilis Solutions Inc.

Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: